GOV UK,Efanesoctocog alfa approved to prevent and treat bleeding in children and adults with severe or moderate haemophilia A
Efanesoctocog Alfa Approved for Preventing and Treating Bleeding in Hemophilia A February 14, 2025 The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for efanesoctocog alfa (Eloctate®), a recombinant factor VIIIa therapy indicated for preventing and treating bleeding episodes in children and adults with severe or moderately severe hemophilia A. Hemophilia … Read more